About this resource:
Source: The Cochrane Collaborative
Last Reviewed: April 2017
Workgroups: Blood Disorders and Blood Safety Workgroup
In this Cochrane systematic review, the Cochrane Collaborative found that hydroxyurea is likely to reduce how often people with sickle cell disease have episodes of pain. Researchers also found that hydroxyurea is likely to prevent first or second strokes in people with the disease who are at risk for stroke. They noted that there isn’t enough evidence to reach a conclusion on long‐term benefits and risks.
Objectives related to this resource (1)
Nevitt, S.J., Jones, A.P. & Howard, J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. (2017). Cochrane Database of Systematic Reviews, 2017 (4). DOI: 10.1002/14651858.CD002202.pub2.